While TCR-modified T cells have been primarily exploited in patients with various solid tumors (e.g., synovial cell carcinoma and melanoma) [29,30], some data from the limited studies done to date in patients with AML, e.g., from a small trial testing an HLA A*02:01-restricted high-affinity Wilms’ Tumor Antigen-1 (WT1)-specific TCR expressed in Epstein–Barr virus (EBV)-specific donor CD8+ T cells in AML patients following allogeneic HCT [31], suggest potential usefulness in this malignancy as well. This evidence concerns the gene CD8A and acute myeloid leukemia.